SI
SI
Advertise on SI

 Biotech / Medical | Biotech Valuation


Previous 10 | Next 10 
To: scott_jiminez who wrote (2208)12/2/2000 12:26:32 PM
From: Bob L   of 40319
 
[OT] While waiting for Justice Suzman to respond to your petition, you might want to look at some of the material on the Presidential Election Law site, edited by a law school dean.
jurist.law.pitt.edu 

The FAQ is particularly useful.
jurist.law.pitt.edu 

The United States Code is the official published collection of laws enacted by the Congress. A code is arranged by topic, somewhat like an encyclopedia, rather than in chronological order of enactment.

Share Recommend | Keep | Reply | Mark as Last Read

To: scott_jiminez who wrote (2208)12/2/2000 2:10:13 PM
From: Biomaven   of 40319
 
(OT) scott,

First a big time disclaimer - it's a long time since my one Constitutional Law class and I haven't dealt with any of this stuff since. (Incidentally I didn't take the class from Tribe - we had a points system for choosing classes which prevented you from taking too many "popular" classes, and I expended my points elsewhere).

Basically what we have is a mixture of a conflict between the Federal system and states' rights compounded by another conflict between the rights of the legislature vs. the rights of the judiciary. Thus there are complex federalism issues mixed with complex separation of powers issues.

The case that may turn out to be central here is an old 1892 case McPherson vs. Blacker. This case is so famous and widely discussed that it is not among the approximately 2500 cases referenced in my old Constitutional Law textbook. <g> Basically it seems to stand for the contention (paraphrasing the Bush brief) that the Florida Supreme Court, relying on the Florida constitution, incorrectly arrogated to itself the power to direct the manner in which the legislators are selected, because these rights are reserved by the US Constitution exclusively to the Florida legislature (and not the Florida Constitution). The Bush team argued (and were backed by Scalia) that the Florida court could not be directed by the Florida constitution in modifying or interpreting the statute. Of course the Florida Supreme court is normally bound by the Florida Constitution, so this is a pretty weird result.

A significant Gore argument is "so what" - worst case is the state loses its "safe harbor" from further challenges to its electors.

I still think Gore will win here, but that it won't make much difference, except perhaps in a PR sense.

BTW, the US code can be seen at:

www4.law.cornell.edu 

Peter

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (2)

To: Biomaven who wrote (2202)12/2/2000 7:56:36 PM
From: tommysdad   of 40319
 
<<But then again there's the data point I have from a friend at a fairly recent IPO that's been selling services to both pharmas and biotechs. His view: "Good luck trying to get a phone call returned from a pharma after lunch on a Friday...">>

Well, sometimes breakthrough drugs do actually come from pharma:

biz.yahoo.com 

STI-571 is truly remarkable. And unlikely to have come from a biotech, IMO. Novartis was in the kinase game big and early.

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (3)

To: tommysdad who wrote (2211)12/2/2000 8:31:42 PM
From: WilderElisimo   of 40319
 
From the Pr, this will be especially interesting to watch, though I hear some observers warn not to expect similar preliminary success.

>Researchers are also investigating the role of Glivec in solid tumors. Novartis recently began a program of small-scale proof of concept studies in selected solid tumors with its agent Glivec, where the biological mechanisms suggest potential activity. These small-scale pilot studies are intended to establish the basis for further studies in clinical trials.<

Share Recommend | Keep | Reply | Mark as Last Read

To: Biomaven who wrote (2210)12/2/2000 9:07:35 PM
From: opalapril   of 40319
 
Here y'ar, Peter. MCPHERSON v. BLACKER, 146 U.S. 1 (1892)

Peter Suzman posts, "This case is so famous and widely discussed that it is not among the approximately 2500 cases referenced in my old Constitutional Law textbook. <g>"

Reading the U.S. Supreme Court decision in McPherson v. Blacker will rudely shake the belief system of anyone who thinks the American political system rests on firm democratic foundations which value the votes of the people.

In 1891 the Michigan legislature changed state law pertaining to the election of Presidential Electors. In effect, Michigan abandoned its previous practice and split the Electors into separate districts. A slate of presidential electors sued, arguing the new state law violated the U.S. Constitution in several regards and asking the state court to order the Michigan secretary of state to revise the ballot so all Electors would be elected at large, as had been Michigan custom.

The state supreme court dismissed the case. The U.S. Supreme Court agreed with the state supreme court, holding that the state legislature was free under the federal constitution to change the method of selecting Electors. The opinion was written by Chief Justice Fuller in his characteristically impenetrable, opaque, and verbose style.
caselaw.lp.findlaw.com 

In upholding the state court decision, Fuller discussed at length the origins of the Electoral College provisions, the alternatives considered, and varying state practices in electing Presidential Electors both before adoption of the Constitution and since. In one key passage, Fuller quotes a then-recent U.S. Senate study of the history of the Electoral College done to lay a predicate for proposed amendment to the Constitution. (Not all contemporary historians agree that the Senate got the history right). Fuller's lengthy quote from the Senate study contains the kernel of what the McPherson case has come to stand for:

"In this report," writes Chief Justice Fuller, "it was said: 'The appointment of these electors is thus placed absolutely and wholly with the legislatures of the several states. They may be chosen by the legislature, or the legislature may provide that they shall be elected by the people of the state at large, or in districts, as are members of congress, which was the case formerly in many states; and it is not [sic] doubt competent for the legislature to authorize the governor, or the [146 U.S. 1, 35] supreme court of the state, or any other agent of its will, to appoint these electors. This power is conferred upon the legislatures of the states by the constitution of the United States, and cannot be taken from them or modified by their state constitutions any more than can their power to elect senators of the United States. Whatever provisions may be made by statute, or by the state constitution, to choose electors by the people, there is no doubt of the right of the legislature to resume the power at any time, for it can neither be taken away nor abdicated.' Senate Rep. 1st Sess. 43d Cong. No. 395."

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (2)

To: tommysdad who wrote (2211)12/2/2000 9:12:21 PM
From: Biomaven   of 40319
 
STI-571 is truly remarkable.

Agreed.

And unlikely to have come from a biotech, IMO. Novartis was in the kinase game big and early.

But then they went and partnered with Vertex on kinase ...

But I do agree that underestimating the pharma is a big mistake. Battleships beat missile frigates most of the time. The key question is my view is whether in the post-genomics environment the battleship advantage will increase or decrease.

Peter

Share Recommend | Keep | Reply | Mark as Last Read

To: opalapril who wrote (2213)12/2/2000 10:45:19 PM
From: Biomaven   of 40319
 
Thanks, opalapril.

Actually a pretty interesting and significant case now that I look at it - as you point out, it certainly undermines the common beliefs about who potentially could elect a President.

I predict it will find its way into the next edition of the textbook. <g>

Peter

Share Recommend | Keep | Reply | Mark as Last Read

To: tommysdad who wrote (2211)12/2/2000 11:20:08 PM
From: Miljenko Zuanic   of 40319
 
<<STI-571 is truly remarkable. And unlikely to have come from a biotech, IMO. Novartis was in the kinase game big and early.>>

Actually, imo, it is more important that this was first drug which rise from basic gene research, from ground zero. Something which is missing in DNA her-2 neu Herceptin.

NVS first pinpoint to specific chromosome, Philadelphia chromosome, that to single gene which was defected, and than that specific Tyr Kin was involved, Abl. Rest is routine. Bit of lack (this kinase is specific and unique, Bcr-Abl), bit of pharma-chemistry and ....

Regards the solid tumor, seams that STI-571 is also PDGF and Kit kinase inhibitor, which may be relevant for NSCLC. Abl kinase isn't important for solid tumor. However, this PDGF/Kin activity rise possibility for side effects.

Miljenko

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)

To: Miljenko Zuanic who wrote (2216)12/3/2000 2:04:37 AM
From: thebeach   of 40319
 
justbiotechs.com 

Share Recommend | Keep | Reply | Mark as Last Read

To: Biomaven who started this subject12/3/2000 12:19:16 PM
From: tuck   of 40319
 
Peter,

Recent comment by Ian Sanderson, Managing Director, Institutional Research at SG Cowen Securities:

>>"On ALZA (NYSE: AZA chart, msgs), you get good visibility on how the primary driver to earnings is doing every Monday morning with the weekly prescription trends of Concerta. Investors will continue to pay what looks on the face of it to be an unreasonable multiple for that type of comfort. And we think that ALZA will continue to move up as long as the Concerta prescription trends and market share do well," Sanderson asserts.<<

Emphasis mine. Is there an independent single source in which such trends are tracked and published? I bet you'd know, and I bet it costs money. Unless he means that he has a source for specifically Concerta & ADHD market. Certainly I've been able to get a lot of figures about that market recently, in terms of how big and who's taking share from whom. But I imagine there's some market research outfit/publication that monitors this stuff and sells reports -- unless they're really nice and just give 'em away -- that Sanderson reads every Monday.

As more biotechs become profitable, we may have to face this sort of prescription trend analysis more often, god forbid!

Cheers, Tuck

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (2)
Previous 10 | Next 10 

Copyright © 1995-2013 Knight Sac Media. All rights reserved.